Trial · NCT00246740

Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting

NCT00246740, Phase 2, Completed, University of Alberta; results first posted 2017-12-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting. Trials, record NCT00246740. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00246740

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
NCT number: NCT00246740
Status: Completed
Phases: Phase 2
Enrollment: 56 participants, actual
Lead sponsor: University of Alberta
Conditions: Coronary Artery Bypass Grafting, Cardiopulmonary Bypass, Reperfusion Injury
Interventions: Periostat, Placebo Oral Tablet
First posted: 2005-10-31
Last updated: 2017-12-15
Results first posted: 2017-12-15
Limitations and caveats: Small sample size. LVSWI does not estimate diastolic dysfunction. Right atrial biopsies may not reflect changes in left ventricular MMP activity. Doxycycline dose- and time-response analyses is required to better assess the protective effects

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Left Ventricular Stroke Work Index (LVSWI)	Before surgery up to 24h of reperfusion	Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g\*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units.
Secondary	Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 μg of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839
Secondary	Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery.
Secondary	Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.
Secondary	Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.
Secondary	Venous Plasma Concentration of Troponin-I	Before surgery and 10 minutes reperfusion after surgery	Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage
Secondary	Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy	Before surgery and 10 minutes reperfusion after surgery	Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH
Secondary	Venous Plasma Concentration of C-reactive Protein	Before surgery and up to 72 h reperfusion after surgery	Measurement of inflammation marker C-reactive protein in plasma
Secondary	Venous Plasma Concentration of IL-6	Before surgery and up to 72 h reperfusion after surgery	Measurement of inflammation marker interleukin-6 in plasma

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Left Ventricular Stroke Work Index (LVSWI)	Before surgery up to 24h of reperfusion	g*m/m2	MEAN
SECONDARY	Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Arbitrary units	MEAN
SECONDARY	Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Arbitrary units	MEAN
SECONDARY	Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Arbitrary units	MEAN
SECONDARY	Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Arbitrary units	MEAN
SECONDARY	Venous Plasma Concentration of Troponin-I	Before surgery and 10 minutes reperfusion after surgery	pg/ml	MEAN
SECONDARY	Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy	Before surgery and 10 minutes reperfusion after surgery	Arbitrary units-Cleaved TnI/GAPDH	MEAN
SECONDARY	Venous Plasma Concentration of C-reactive Protein	Before surgery and up to 72 h reperfusion after surgery	ng/ml	MEAN
SECONDARY	Venous Plasma Concentration of IL-6	Before surgery and up to 72 h reperfusion after surgery	pg/ml	MEAN

Source ClinicalTrials.gov

Results by group94

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Left Ventricular Stroke Work Index (LVSWI)	Placebo Oral Tablet	Before surgery	42	Standard Error 2.6	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Periostat	Before surgery	43	Standard Error 2.5	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Placebo Oral Tablet	Post surgery	29	Standard Error 1.7	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Periostat	Post surgery	28	Standard Error 1.7	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Placebo Oral Tablet	1h reperfusion	30	Standard Error 1.8	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Periostat	1h reperfusion	29	Standard Error 1.9	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Placebo Oral Tablet	3h reperfusion	31	Standard Error 1.9	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Periostat	3h reperfusion	29	Standard Error 2	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Placebo Oral Tablet	6h reperfusion	28	Standard Error 1.4	g*m/m2
Left Ventricular Stroke Work Index (LVSWI)	Periostat	6h reperfusion	25	Standard Error 1.4	g*m/m2

1 to 10 of 94Source ClinicalTrials.gov

See all 94 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Initial Enrollment	STARTED	Placebo Oral Tablet	28
Initial Enrollment	STARTED	Periostat	28
Initial Enrollment	COMPLETED	Placebo Oral Tablet	22
Initial Enrollment	COMPLETED	Periostat	20
Initial Enrollment	NOT COMPLETED	Placebo Oral Tablet	6
Initial Enrollment	NOT COMPLETED	Periostat	8
Experimental Phase	STARTED	Placebo Oral Tablet	22
Experimental Phase	STARTED	Periostat	20
Experimental Phase	COMPLETED	Placebo Oral Tablet	22
Experimental Phase	COMPLETED	Periostat	20

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo Oral Tablet	22
Total, all-cause mortality	Periostat	20
Total, other adverse events	Placebo Oral Tablet	22
Total, other adverse events	Periostat	20
Total, serious adverse events	Placebo Oral Tablet	22
Total, serious adverse events	Periostat	20

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23928836	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Periostat vs Placebo Oral Tablet: deaths from any cause	Trial comparisons
Periostat vs Placebo Oral Tablet: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00246740

GET https://conductscience.org/api/trials/v1/NCT00246740/results?page=2

API reference For AI assistants